The FDA gave an investigational device exemption to spine devicemaker 3Spine.
The exemption will allow 3Spine to study its Motus device in a clinical trial, according to a June 22 news release. The company finished contracting and site initiation at 16 U.S. centers for a prospective study.
Motus is an implant used in the BalancedBack total joint replacement procedure. It is designed to address leg pain, back pain and spinal instability, 3Spine said.